Adjuvant Capital
Overview
Adjuvant Capital is a life sciences investment firm focused on global health.
Investment Focus
- Innovative technologies addressing high-burden infectious diseases
- Demonstrated safety and efficacy in humans
- Potential for global availability and impact
- Alignment with global health trends and challenges
- Commitment to social and financial returns for investors
Portfolio Companies
Reach Adjuvant Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Adjuvant Capital
What sectors does Adjuvant Capital invest in?
Adjuvant Capital invests in Healthcare, Pharmaceuticals, Medical Devices, Diagnostics, Biotechnology and Infectious Diseases, and is based in New York. Adjuvant Capital is listed as a vc in the ConnectSafely investor database.
What stage does Adjuvant Capital invest at?
Adjuvant Capital backs companies at Early Stage and Growth, writing cheques of 5M - 25M.
Which regions does Adjuvant Capital invest in?
Adjuvant Capital invests across United States, Denmark and Switzerland.
Who are the partners at Adjuvant Capital?
Team members listed for Adjuvant Capital include Glenn Rockman (Founder and Managing Partner) and Kabeer Aziz (Partner).
What companies has Adjuvant Capital invested in?
Adjuvant Capital's portfolio includes LimmaTech Biologics, Minervax, Memo Therapeutics, Curevo and 54gene.
How do I contact Adjuvant Capital?
Adjuvant Capital's contact details — including work email, phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database